FDA warning reminds us of labeling's impact
from Healthcare Packaging
Seemingly basic details, such as a product's name or the amount of drug in a tablet, can pose potential patient safety risks if that information is confusing or inaccurate, as two current examples attest. What's in a name? Plenty, according to the U.S. Food and Drug Administration. On Feb. 17, the agency noted that Novartis Consumer Health Inc. "agreed to change the name of Maalox Total Relief to one that does not include the word 'Maalox' and will change the drug's packaging to avoid further confusion."
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063